On December 18, 2025, Athira Pharma, Inc. reported a private placement financing of approximately $90 million involving 5,356,547 shares and warrants, as well as exclusive licensing agreements for developing lasofoxifene, a selective estrogen-receptor modulator, outside Asia, with associated payments up to $100 million based on milestones. This filing reflects significant financial activity and strategic partnerships for the company.